---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-148897"
form_type: "8-K"
ticker: "LYEL"
cik: "0001806952"
company_name: "Lyell Immunopharma, Inc."
filed_at: "2025-06-26T23:59:59+00:00"
generated_at: "2026-05-18T18:10:26.155623+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Lyell Immunopharma to issue 625,000 shares upon achieving CAR T-cell clinical milestone

## Summary
- Milestone for ImmPACT's next-gen CAR T-cell candidate achieved on June 20, 2025.
- 625,000 shares of common stock (post-1-for-20 reverse split) to be issued to ImmPACT securityholders.
- Shares issued in private placement exempt under Section 4(a)(2) of the Securities Act.
- Issuance is contingent consideration from the previously completed ImmPACT Bio merger.

## SEC filing metadata
- accession: 0001193125-25-148897
- form_type: 8-K
- ticker: LYEL
- cik: 0001806952
- company_name: Lyell Immunopharma, Inc.
- filed_at: 2025-06-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 3.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806952/000119312525148897/0001193125-25-148897-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806952/000119312525148897/d917552d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-148897
- JSON: https://secwatch.observer/filing/0001193125-25-148897.json
- Plain text: https://secwatch.observer/filing/0001193125-25-148897.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.